In summary, our results highlight the difficulty in reducing pathway activity to singular genomic alterations and demonstrate that this is particularly true in the case of EGFR in primary and recurrent glioblastoma, outlining the need to better understand the factors mediating gene pathway expression in these patients [28,29]. Here, EGFR is linked to glioblastoma.